PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VIR vs. DNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Performance

VIR vs. DNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vir Biotechnology, Inc. (VIR) and Ginkgo Bioworks Holdings, Inc. (DNA). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%JuneJulyAugustSeptemberOctoberNovember
-27.44%
-79.39%
VIR
DNA

Returns By Period

In the year-to-date period, VIR achieves a -30.12% return, which is significantly higher than DNA's -90.64% return.


VIR

YTD

-30.12%

1M

-7.86%

6M

-27.45%

1Y

-27.45%

5Y (annualized)

-10.86%

10Y (annualized)

N/A

DNA

YTD

-90.64%

1M

-28.72%

6M

-79.34%

1Y

-89.59%

5Y (annualized)

N/A

10Y (annualized)

N/A

Fundamentals


VIRDNA
Market Cap$1.27B$366.14M
EPS-$3.93-$12.89
Total Revenue (TTM)$78.62M$217.95M
Gross Profit (TTM)$64.40M$138.89M
EBITDA (TTM)-$499.25M-$626.41M

Key characteristics


VIRDNA
Sharpe Ratio-0.44-0.90
Sortino Ratio-0.35-2.29
Omega Ratio0.960.76
Calmar Ratio-0.30-0.90
Martin Ratio-1.11-1.40
Ulcer Index24.45%63.92%
Daily Std Dev61.94%99.34%
Max Drawdown-91.54%-99.10%
Current Drawdown-91.54%-98.94%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Correlation

-0.50.00.51.00.4

The correlation between VIR and DNA is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Risk-Adjusted Performance

VIR vs. DNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for VIR, currently valued at -0.44, compared to the broader market-4.00-2.000.002.004.00-0.44-0.90
The chart of Sortino ratio for VIR, currently valued at -0.35, compared to the broader market-4.00-2.000.002.004.00-0.35-2.29
The chart of Omega ratio for VIR, currently valued at 0.96, compared to the broader market0.501.001.502.000.960.76
The chart of Calmar ratio for VIR, currently valued at -0.31, compared to the broader market0.002.004.006.00-0.31-0.90
The chart of Martin ratio for VIR, currently valued at -1.11, compared to the broader market-10.000.0010.0020.0030.00-1.11-1.40
VIR
DNA

The current VIR Sharpe Ratio is -0.44, which is higher than the DNA Sharpe Ratio of -0.90. The chart below compares the historical Sharpe Ratios of VIR and DNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.000.200.40JuneJulyAugustSeptemberOctoberNovember
-0.44
-0.90
VIR
DNA

Dividends

VIR vs. DNA - Dividend Comparison

Neither VIR nor DNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

VIR vs. DNA - Drawdown Comparison

The maximum VIR drawdown since its inception was -91.54%, smaller than the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for VIR and DNA. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%-80.00%JuneJulyAugustSeptemberOctoberNovember
-87.11%
-98.94%
VIR
DNA

Volatility

VIR vs. DNA - Volatility Comparison

Vir Biotechnology, Inc. (VIR) has a higher volatility of 29.58% compared to Ginkgo Bioworks Holdings, Inc. (DNA) at 27.50%. This indicates that VIR's price experiences larger fluctuations and is considered to be riskier than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%JuneJulyAugustSeptemberOctoberNovember
29.58%
27.50%
VIR
DNA

Financials

VIR vs. DNA - Financials Comparison

This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items